Acute Myeloid Leukemia Clinical Trial
Official title:
An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
The trial is a multi-centre, open-label, safety and tolerability extension trial to the IPH2101-101 (previously NN1975-1733) first human dose trial completed with a larger subject pool at an optimal dose level. The trial is conducted in elderly Acute Myeloid Leukemia (AML) patients over the age of 60 years, in complete remission, and who are not eligible for allogeneic stem-cell transplantation. The dose given to the individual patient will be the same as the patient received in the single dose trial IPH2101-101 and 1 mg/kg or 2 mg/kg for the 12 patients in an additional cohort.
Status | Completed |
Enrollment | 21 |
Est. completion date | September 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Informed consent obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject) 2. Acute myeloid leukaemia (AML) according to WHO Criteria 3. Morphological complete remission (CR) defined according to NCI criteria, or CRi with incomplete platelet count recovery only after 1 or 2 cycles of induction chemotherapy, and at least 1, and maximally 6 cycles of consolidation chemotherapy: - Absolute neutrophile count > 1x 109/L - Platelets > 80x109/L - Independency of blood transfusions - Less than 5% blasts in bone-marrow - No Auer rods - No symptoms of disease 4. Life expectancy > 4 months as judged by the Investigator 5. The patient is > or = 60 years of age but < or = 80 years of age 6. The patient has completed participation in the IPH2101-101(previously NN1975-1733)trial with an acceptable safety profile, as judged by the Investigator or is screened for the additional cohort 7. Time since last dose of chemotherapy at least 30 days and no more than 60 days if the patient did not participate in IPH2101-101 trial before 8. Recovery from acute toxicities of all previous anti-leukaemic therapies 9. KIR-expression on patient NK-cells (ability to bind Anti-KIR(1-7F9)) if the patient did not participate in IPH2101-101 trial before 10. ECOG performance status 0, 1 or 2 11. No major organ dysfunction as judged by the Investigator 12. The patients must have the following clinical laboratory values: - Serum creatinine < or = 2 md/dL - Total bilirubin < or = 1.5 x the upper limit of normal - Asparatate aminotransferase (AST) < 3x the upper limit of normal Exclusion Criteria: 1. Known or suspected allergy to trial product or related products 2. Previous participation in this trial 3. AML classified as FAB M3 (APL, acute promyelocytic leukaemia) or with good prognosis AML i.e. t(8;21)(q22;q22) or inv(16)(p13q22) or t(16;16)(p13;q22) or their molecular equivalents 4. Eligibility for allogeneic haematopoietic transplantation 5. The patient is currently receiving, or has within the last 4 weeks received other investigational anti-leukemic treatment such as cytokine treatment, except Anti-KIR(1-7F9) 6. The patient has received G-CSF treatment within the last 30 days prior to screening 7. Systemic steroid treatment within the last 4 weeks prior to screening 8. Patient has active autoimmune disease 9. Diagnosis of monoclonal gammopathy 10. Patient has active infectious disease 11. Previous leukaemic CNS involvement 12. Cardiac failure (New York Heart Association [NYHA] grade III-IV) 13. Left ventricular ejection fraction (LVEF) less than 45 % of normal evaluated by ultrasound or isotopic evaluation 14. Severe neurological/psychiatric disorder 15. HIV or chronic hepatitis infection 16. Clinical evidence of an active second malignancy 17. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation 18. Any new medical condition that in the opinion of the Investigator disqualifies the patient for inclusion |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hopital Dupuytren | LIMOGES Cedex | |
France | Institut Paoli-Calmettes | Marseille | Marseille Cedex 09 |
France | C.H.R.U. de Nantes - Hotel Dieu | NANTES Cedex 1 | |
France | Centre Hospitalier Lyon Sud - Hospices Civils de Lyon | Pierre-Bénite | |
France | Hopital de Purpan | Toulouse Cedex 9 | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Innate Pharma |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess safety and tolerability of repeating dosings of Anti-KIR(1-7F9) | using the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) | every 2 weeks | Yes |
Secondary | To assess the pharmacokinetics upon repeated dosing(s)of Anti-KIR(1-7F9) | every 2 weeks | No | |
Secondary | To assess the pharmacodynamics upon repeated dosing(s) of Anti-KIR(1-7F9) | Degree of KIR-occupancy on patient NK-cells Plasma inflammatory cytokines (IFN-?, TNF-a, IL-1, IL-6) Immunophenotyping (NK-, B- and T-lymphocyte counts and activation status) NK-cell surface markers (activation markers and inhibitory receptors) Functional assay of NK-cell activity only for patient from additional cohort |
every 2 or 4 weeks | No |
Secondary | To assess signs of efficacy of repeated dosing(s) with Anti-KIR(1-7F9) | Reduction in minimal residual disease measured by WT-1 expression in blood and bone marrow Progression-free survival (measured as calendar days from the first dosing of Anti-KIR(1-7F9) (in the IPH2101-101 trial) to date of progression diagnosed or until death by any cause Overall survival measured as calendar days from the first dosing of Anti-KIR (1-7F9) to date of death |
to date of progression diagnosed or until death | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |